CGT Industrial Park Tour Episode 9: Chengdu Tianfu International Biomedical City Sets Off!

Event Time：Tuesday, July 16, 2024, 13:30

Event Venue：Hyatt Place Chengdu Bio-town, No. 1 Huigu Road, Shuangliu District, Chengdu

Organizer:Healthcare Innovative Ecosystem Alliance (HIEA)

Co-organized by:Hangzhou Xingcheng Biotechnology, Yeasen, LePure Introduction, VectorBuilder, Hong Kong Austar Group, Danaher Life Sciences, Levostar Biotechnology, Legend Capital

Co-organizers:Chengdu Guosheng Innovation Technology Service Co., Ltd.

Organizer:VCBeat New Medicine

Since November 2023, VBInsight, in collaboration with enterprises across the upstream and downstream CGT industry chain, has held a total of eight events in Shanghai, Nanjing, Suzhou, Beijing, Guangzhou, and Shenzhen.CGT Industry Upgrade"Series of Park Tours". Invite decision-makers from innovative enterprises and service providers across the industry chain to share the stage, voice their needs, speak candidly, and foster communication, connection, and co-creation of high-quality products.

Amid the ongoing capital winter, strengthening CMC capabilities, exploring investment and financing opportunities, pursuing international expansion, and maintaining operational viability have become core strategic imperatives that innovative pharmaceutical companies must urgently address.

Based on this, byHosted by the Healthcare Innovative Ecosystem Alliance (HIEA), co-hosted by Xingcheng Biotechnology, Yeasen, LePure Biotechnology, VectorBuilder, Austar Group, Danaher Life Sciences, Zuoxuanxing Biotechnology, and Legend Capital, with support from Chengdu Tianfu International Bio-town, and organized by VBNewMed.【Go Further Without the Rat Race】CGT Industry Upgrade Series · Park Tour Stop 9, to be held on July 16 (Tuesday) at the Hyatt Place Hotel in Chengdu Biological Town.

CGT from an Investment Perspective:Leveraging the strategic insights of investors and corporate business development leaders, this analysis distills new pathways for innovative pharmaceutical companies to secure funding, helping them navigate growth opportunities and challenges.

Optimal Supply Chain Solutions for Extraordinary Times:Listening to the client’s needs, supply chain companies collaborate to explore the most suitable solutions, striving to help innovative enterprises transition smoothly, rapidly, and cost-effectively from preclinical stages to Investigational New Drug (IND) applications and other key milestones.

Global Insights · CGT Quality Management:Focusing on the Frontier: An In-Depth Exploration of End-to-End Quality Control in Cell and Gene Therapy. Unveiling the Impact of Global Regulations, Analyzing Success Stories, Empowering Enterprises to Build Efficient and Compliant Systems, and Safeguarding the Delivery of Innovative Therapies to Patients Worldwide.

■ 13:30-13:40  Opening

Host | Event Expectations and Ecosystem Synergy

Park Leadership | Park Introduction and Future Outlook

■ 13:40-14:00  Keynote Speech 1

Themed Sharing by the Rotating Co-organizer

Xingcheng Biotechnology

■ 14:00-14:20  Keynote Speech 2

Thematic Sharing by the Rotating Co-organizer

Yeasen

■ 14:20-14:40  Keynote Speech 3

Thematic Sharing by the Rotating Co-organizer

LevoStar Biotech

■ 14:40-15:00  Keynote Speech 4

Thematic Sharing by the Rotating Co-organizer

Danaher Life Sciences

■ 15:00-15:50  Panel1

How to Support CGT Projects from Preclinical Stage to Key Milestones,

Stable, Fast, Cost-Effective?

· Discussion on Quality Control Strategies and Specific Service Cases

· Party A states its requirements, and Party B proposes solutions

· How to Maintain Positive Engagement with Clients and Foster Mutual Support During Challenging Times

2–3 CGT companies + 2–3 co-organized enterprises

■ 16:10-16:30 Keynote Speech 5

Discussion of Current Hot Topics

Industry Leaders

■ 16:30-16:50  Keynote Speech 6

In Global For Global

——Reflections on Trends in Cell and Gene Therapy

Legend Capital

■ 16:50-17:40  Panel2

How Can CGT Companies Effectively Pursue Financing and Business Development in the New Landscape?

· Anecdotes from BD Partnership Negotiations

·How to Balance Fundraising and Business Development

· Use "preparation" to respect uncertainty

4-5 CGT Companies + Investment Institutions

Event Scale: 50 people/session

Event Registration:

Capillaries 17782369627 (WeChat ID same as phone number)

Event Partnership:

Ms. Fu 17851017836 (WeChat ID same)

👇Long-press to scan the QR code and register👇

CoJourney is a professional gene andCell Therapy CDMO. Proven track record of successful Investigational New Drug (IND) applications in China and the United States for plasmids and viral vectors, achieved with zero deficiency letters. Provides customized services including process development, cGMP manufacturing, analytical method development, and product testing and release for plasmids, viral vectors, and mRNA.

Hangzhou Xingcheng Biotechnology Co., Ltd. was co-founded by senior CMC experts with commercialization experience in the gene and cell therapy fields, alongside accomplished scientists and entrepreneurs. With dual headquarters located in Zhejiang, China, and Pennsylvania, USA, the company has established GMP manufacturing facilities for plasmids, viral vectors, and mRNA that comply with FDA, EU, and NMPA regulations. Equipped with advanced production and analytical instrumentation, and backed by a team with extensive process development expertise and practical experience, Xingcheng Biotechnology adheres to the philosophy of “Action Rooted in Sincerity.” The company leverages robust processes that exceed industry standards to provide partners with high-purity, high-yield, and cost-effective services for the preparation of plasmids, viral vectors, and mRNA at various production scales, ranging from R&D to GMP grade.

Yisheng Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise focused on core raw materials in the upstream segment of the life science industry chain, engaged in the research and development, production, and sales of biological reagents across three major categories: molecular, protein, and cellular products. By integrating technological development pathways for molecular enzymes, proteins, antibodies, nucleic acids, and cells, Yeasen has become one of the few companies in China that simultaneously covers all three major categories of biological reagents, possessing both independent R&D capabilities for core technologies and large-scale production capacity.

The company develops, manufactures, and sells thousands of types of biological reagents, meeting customers’ integrated procurement needs for various categories of biological reagents. Its core product portfolio covers the qPCR series,NGSReverse Transcription Series, Nucleic Acid Extraction and Purification Series, PCR Series, Molecular Cloning Series, In Vitro Transcription Series, Antibodies, Protein Purification Series, Protein Analysis Series, Recombinant Proteins, Cell Analysis Series, Cell Culture Series, Cell Transfection Series, Reporter Gene Assay Series, and other categories, which are widely used in life science research, diagnostic testing, biopharmaceuticals, and other fields.

Shanghai LePure Biotechnology Co., Ltd. was established in 2011 and has integrated outstanding brands such as Geshi Fluid, Kangsheng Biology, and Stanleys through an external growth strategy. Its current business scope covers multiple application scenarios, including cell culture, filtration and purification, single-use systems, and industrial-grade contamination-free clean solutions. It has now become a widely recognized leading supplier of end-to-end upstream pharmaceutical processes within the industry.

Mission & Vision: Driven by technological innovation, we provide high-quality bioprocessing solutions and are committed to becoming the most trusted partner for global biopharmaceutical companies.

VectorBuilder (Guangzhou) Biotechnology Co., Ltd. was founded in 2014 by Dr. Tian Lan, a world-renowned molecular biologist, and has emerged as a leading enterprise in gene delivery. The company provides comprehensive services across the entire gene delivery industry chain, including research vector construction, gene delivery CRO, and gene vector CDMO. With more than 10 subsidiaries and offices worldwide, VectorBuilder was recognized as a global unicorn in 2023. Its proprietary “VectorBuilder” platform pioneered the commercialization of customized gene vectors, serving over 4,000 research institutions and pharmaceutical companies in more than 90 countries and regions. Research outcomes facilitated by its services have been widely cited in thousands of articles published in top-tier scientific journals such as Science, Nature, and Cell. Since entering the clinical market, its gene therapy CRO and CDMO projects have expanded to cover multiple countries and regions, including North America, Europe, and Japan.

Yunzhou Bio offers end-to-end services from research to clinical applications:

1. Research Vectors and Viral Services

Vector construction, viral packaging, etc.

2. CRO Services

AAV capsid directed evolution, library construction, mRNA gene delivery solutions, stable cell line generation, etc.

3. CDMO Services

Process development, analytical method development, plasmid preparation, virus preparation, IVT mRNA and LNP preparation, cell bank establishment, etc.

Yunzhou Biotech is dedicated to systematically overcoming key technical bottlenecks in the gene delivery industry, empowering basic scientific research, accelerating the clinical application of gene therapies, improving human health, and creating irreplaceable value for the world.

Hong Kong Austar Group is an advanced technology-driven provider of pharmaceutical engineering solutions, with comprehensive knowledge and expertise in life sciences process technologies, applications, industry regulatory standards, and best practices. The company helps clients address challenges related to quality, compliance, and operational excellence, and is committed to delivering turnkey solutions encompassing equipment, engineering, services, and consumables, thereby driving industry progress and creating sustained value.

Austar Life Science Equipment and Consumables is a key business unit of Austar Group. By introducing advanced research, industrial consumables, and instrumentation from Europe and the United States, we provide comprehensive, high-quality solutions encompassing consumables, equipment, and services for industries such as pharmaceuticals, life sciences, laboratory animal science, biosafety, medical devices, health supplements, and daily chemicals. We cater to clients requiring compliance with EU GMP, cGMP, COS, and other relevant certifications, offering diversified technical guidance, training, and application support.

At Danaher, we converge science, technology, and operational expertise to accelerate the impact of future technologies on today’s lives. We partner with customers worldwide to design solutions that address their most complex challenges, turning the power of science into reality. Our global team is shaping the future of life sciences, medical diagnostics, biotechnology, and more. The Danaher Life Sciences platform serves leading life sciences companies globally, accelerating breakthrough innovations to enable healthier lives for humanity. We maintain long-term collaborations with scientists in research, clinical, and government institutions, leveraging our strengths in science and operations to help them deepen their understanding of disease principles and mechanisms, develop more effective therapies, and create more efficient workflows. Together, we accelerate the positive impact of life sciences on human life.

Danaher China Life Sciences Platform was established on June 1, 2019, with the aim of rooting itself in the Chinese market to provide superior products and services to users in China, focusing on creating comprehensive integrated solutions for precision medicine and biopharmaceuticals. The platform currently boasts numerous well-known brands, including IDT (Integrated DNA Technologies), Beckman Coulter Life Sciences, Molecular Devices, SCIEX, Agela-Phenomenex, Leica Microsystems, Aldevron, and Pall. In the fields of precision medicine and biologics, Danaher Life Sciences continuously develops and refines relevant analytical solutions and workflows based on the actual application scenarios of its Chinese customers. It currently offers rich, multi-dimensional solutions in areas such as synthetic biology, multi-omics research, organoid research, precise tumor diagnosis and treatment, infectious disease detection, and maternal and child health testing. Furthermore, it provides comprehensive, mature, and highly competitive end-to-end solutions—from R&D to quality control analysis—for a wide range of biologics, including antibody drugs, gene therapies, cell therapies, nucleic acid drugs, and novel vaccines.

LevoStar Biotech is a technology-driven enterprise dedicated to the development of foundational technologies for innovative therapies and their efficient manufacturing, aiming to provide leading-edge technologies and comprehensive solutions for nucleic acid drugs and cell and gene therapy (CGT) products. The company boasts multiple core technology platforms, including traceable plasmid synthesis, plasmid process development and manufacturing, RNA synthesis and delivery, as well as analytical method development and quality research for nucleic acid and CGT drugs, delivering end-to-end solutions from sequence design to RNA drug production.

In the development of foundational RNA technologies, Levostar Bio possesses industry-leading capabilities. The company’s monoPlasmid platform leverages cutting-edge patented synthetic biology technologies, centered on its mRNA-specific pLevoD series plasmids and proprietary engineered bacterial strains. By combining directed evolution with AI-driven screening, the platform has innovatively optimized plasmid control elements and edited specific host strains. This approach effectively suppresses multimer formation while maintaining the stability of the plasmid Poly(A) tail across multiple generations, thereby addressing multiple CMC challenges associated with mRNA plasmids in a single integrated solution.

LevoStar Biotech adheres to the principles of professionalism, integrity, openness, pragmatism, equality, and mutual benefit, aiming to collaborate with biopharmaceutical companies to accelerate medical innovation and support drug development, thereby keeping diseases at bay for everyone.

Legend Capital was established in April 2001 and is a leading fund management company in China specializing in early-stage venture capital and growth-stage private equity investment. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through its proactive value-added service system, Legend Capital drives innovative corporate growth, consistently delivering strong investment returns across multiple sectors while promoting industrial advancement and social development in China. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Wealth with Integrity” and actively fulfills its social responsibilities.

Legend Capital has maintained a deep focus on investments in the healthcare sector, systematically building its portfolio across the broader health industry. Notable portfolio companies in this field include Pharmaron (300759.SZ) (03759.HK), WuXi AppTec (603259.SH) (02359.HK), and WuXi Biologics (02269.HK),Innovent Biologics(01801.HK), New Horizon Health (06606.HK), and Mingde Biology (002932.SZ), among other niche industry leaders, are listed on the A-share and Hong Kong stock markets.

Chengdu Tianfu International Bio-town is a specialized bio-industry park jointly established by Chengdu High-Tech Zone and Shuangliu District in 2016, covering an area of approximately 44 square kilometers. Ranked fourth among national biomedical parks by the Ministry of Science and Technology, Chengdu Tianfu International Bio-town aims to become a global hub for innovation and entrepreneurship in pharmaceuticals and healthcare, striving to build a world-class center for biological industry innovation and intelligent manufacturing.

BioCity focuses on the “5+18” industrial directions, implementing targeted investment promotion and precise cultivation. Specifically, it aims at five major sub-sectors and 18 tracks to form a cluster of industrial groups. To date, it has partnered with over 2,600 enterprises, introduced more than 400 projects, and attracted total investments exceeding RMB 120 billion.

BioCity focuses on building specialized industrial parks. Currently, the total area of delivered and under-construction facilities exceeds 1 million square meters, aiming to provide integrated innovation platforms that combine “incubation seeding, business incubation, R&D, and pilot-scale testing,” thereby offering professional supporting services to biopharmaceutical enterprises.